Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation
Omega Diagnostics Gp (AIM:ODX) Change of preliminary results date
Change of preliminary results date and investor presentation and update to CD4 sale
Omega Diagnostics Gp (AIM:ODX) Completion of Sale of the CD4 Business
Completion of Sale of the CD4 Business
Omega Diagnostics Heads of Terms agreed for Sale of CD4 Busines
Omega Diagnostics Group PLC, (AIM: ODX). announced that it has selected a preferred bidder for its CD4 business after having made an announcement nearly two months back.
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Omega Diagnostics Gp (AIM:ODX) Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces the results of its Open Offer.
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
Angle PLC (AIM:AGL) receives FDA clearance for Parsortix
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM
Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Omega Diagnostics Gp (AIM:ODX) Placing, Subscription and Open Offer
Placing of 50,000,000 New Ordinary Shares and Warrants
Omega Diagnostics Gp (AIM:ODX) Trading Update
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
